Global expansion CPC Scientific is actively expanding its US GMP manufacturing footprint with a new state-of-the-art facility in the United States to strengthen supply chain resilience and meet growing demand in North America, presenting opportunities to engage on localized manufacturing partnerships, faster scale-ups, and regional regulatory support.

CRDMO specialization As a focused CRDMO expert in GMP peptides, oligonucleotides, and POCs, CPC Scientific offers end-to-end support from discovery to commercial production, which can be positioned to contract efficiently for late-stage development, scale-up, and regulatory filings to accelerate IND/NDA/BLA timelines.

Regulatory readiness The company emphasizes CGMP compliance and robust regulatory support across US and international filings, providing potential value through regulatory strategy, method validation, stability studies, and NCE development programs that can reduce time-to-market and de-risk complex programs.

Industry engagement Active participation in RNA and peptide related conferences (RNA Leaders Congress, Boulder Peptide Symposium, BPS) signals market visibility and networking opportunities to target customers pursuing RNA therapeutics, peptide drugs, and vaccine-related manufacturing needs.

Financial and scale potential With a revenue range of tens of millions and a leaner organization, CPC Scientific presents an attractive partner for mid-size biotech firms seeking scalable manufacturing, rapid project onboarding, and flexible capacity to support IND-enabling work and large-scale production.